This product is for professional laboratory research applications exclusively
OMIM #277380, cblJ

Semaglutide is prescribed for: Weight loss in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) Weight loss in adult patients with an initial body mass index (BMI) of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (hypertension, type 2 diabetes mellitus, or dyslipidemia) Weight loss in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity) Reducing the risk of major adverse cardiovascular events (non-fatal myocardial infarction, CV death, or non-fatal stroke) in adults with cardiovascular disease and either obesity or overweight Treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis (stages F2 to F3 fibrosis) in adults Patients taking semaglutide for any of these conditions, especially weight loss, are typically suggested to maintain a low-carb and low-fat diet

In addition, BPC-157 has been studied for its potential in treating conditions like osteoarthritis, rheumatoid arthritis, and osteoporosis
This effect was actually noted in a small chart review in humansone of the few uses of BPC-157 that has human evidence at this time [7]
Other risk factors for shin splints includes your arch height (too flat or too high are both a problem.) Also, training on hard, surfaces (like concrete) can increase your risk for this injury